The goal of this randomized clinical trial is to evaluate the clinical and radiographic success of pulpotomy using Neoputty MTA vital primary molars diagnosed with symptomatic irreversible pulpitis. The main question it aims to answer is: Will Neoputty MTA pulpotomy have higher clinical and radiographic success in comparison to Endoflas pulpectomy in primary molars with irreversible pulpitis?
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
66
Neoputty MTA pulpotomy performed in vital primary molars with symptomatic irreversible pulpitis
Endoflas pulpectomy in vital primary molars with symptomatic irreversible pulpitis
postoperative pain
postoperative pain will be assessed using the visual analogue scale (VAS) within 24 hours, after 1 week, 3, 6, 9, and 12 months. The patients are asked to point to the face that best represents how they are feeling at the follow-up visits.
Time frame: within 24 hours, after 1 week, 3, 6, 9, and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.